Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07315360 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

A Phase 1 study of Healthy and Renal Impairment, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
28
Enrollment target
4
Study locations

NCT07315360 is a Phase 1 study of Healthy and Renal Impairment that is actively recruiting participants, run by Pfizer. The registered enrollment target is 28 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07315360, a Phase 1 study of Healthy and Renal Impairment, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
28 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to learn how the study medicine PF-07328948 is processed by the body and how safe and tolerable it is in adults with different levels of kidney function. The study will include participants who: * Are aged 18 to 80 years. * Either have normal kidney function or long-term reduced kidney function (moderate or severe). * Have a BMI (body mass index) of 17.5 to 40 kilogram per meter squared, inclusive, and a total body weight of more than or equal to 45 kilograms or 99 pounds. All participants will receive a single dose of PF-07328948 as a tablet taken by mouth. Participants will stay at a clinical research unit for about 6 days to receive the study medicine and undergo safety checks. Total participation lasts up to 64 days, including screening, inpatient stay, and a follow-up call. The study is not randomized or blinded, meaning all participants and study staff know which treatment is being given. Group assignment is based on kidney function tests done during screening. The results will help researchers understand how reduced kidney function affects the way PF-07328948 works in the body.

Conditions Studied

Healthy Renal Impairment

Interventions

  • DRUG PF-07328948

Study Locations (4)

Florida

  • Orlando Clinical Research Center - Orlando
  • Genesis Clinical Research, LLC - Tampa

California

  • Orange County Research Center - Lake Forest

Minnesota

  • Nucleus Network - Saint Paul

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2026-01-28
Est. Completion 2027-03-13
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07315360

The ClinicalTrials.gov registry entry for NCT07315360 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PF-07328948 is the first listed.

NCT07315360 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT07315360 about?

NCT07315360 is a clinical study titled "A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function". The purpose of this study is to learn how the study medicine PF-07328948 is processed by the body and how safe and tolerable it is in adults with different levels of kidney function. The study will include participants who: * Are aged 18 to 80 years. * Either have normal kidney function or long-te...

What is the current status of trial NCT07315360?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-01-28. Estimated completion is 2027-03-13.

What conditions does trial NCT07315360 study?

This clinical trial studies the following conditions: Healthy, Renal Impairment.

What interventions are being tested in trial NCT07315360?

The interventions under investigation include: PF-07328948 (DRUG).

Who is sponsoring clinical trial NCT07315360?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07315360 being conducted?

This trial has 4 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Renal Impairment

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.